Shares of Second Sight Medical Products Inc. (NASDAQ:EYES) traded at a new 52-week high today of $14.82. Approximately 94.5 million shares have changed hands today, as compared to an average 30-day volume of 26.6 million shares.
Second Sight Medical Products Inc. (NASDAQ:EYES) is currently priced 51.2% above its average consensus analyst price target of $5.49.
Second Sight Medical Products Inc develops, manufactures and markets implantable prosthetic devices, to create an artificial form of useful vision for blind individuals. The company’s product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, France and Germany, of which key revenue is derived from the United States.
In the past 52 weeks, shares of Second Sight Medical Products Inc. have traded between a low of $0.69 and a high of $14.82 and is now at $11.24, which is 1,528% above that low price.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer